| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
ATYR sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 779.1K | $386.7K | - | |
| CEO | 153.6K | $149.9K | - | |
| CFO | 37.3K | $36.4K | - | |
| Other | 33.1K | $32.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 27, 2026 | Schimmel Paul53 | Director | Buy | 100,000 | $0.50 | $49,630.00 | +14.7% | +19.2% | - | |
| Feb 4, 2026 | Shukla Sanjay66 | President and CEO | Sale+OE | 3,745 | $0.98 | $3,655.12 | -2.4% | -4.4% | - | |
| Feb 4, 2026 | Denyes Nancy | General Counsel | Sale+OE | 1,118 | $0.98 | $1,091.28 | -3.3% | -4.4% | - | |
| Feb 4, 2026 | Broadfoot Jill Marie61 | Chief Financial Officer | Sale+OE | 1,558 | $0.98 | $1,520.61 | -4.0% | -4.4% | - | |
| Oct 9, 2025 | Schimmel Paul53 | Director | Buy | 1,000,000 | $0.91 | $911,801.16 | +242.1% | -21.7% | -74.2% | |
| Mar 17, 2025 | Gross Jane A | Director | Buy | 3,750 | $4.00 | $15,000.00 | +62.5% | +36.7% | -78.0% | |
| Feb 4, 2025 | Broadfoot Jill Marie61 | Chief Financial Officer | Sale+OE | 1,254 | $3.78 | $4,740.12 | -3.8% | -6.0% | -76.9% | |
| Feb 4, 2025 | Denyes Nancy | General Counsel | Sale+OE | 899 | $3.78 | $3,398.22 | -3.3% | -6.0% | -76.9% | |
| Jul 24, 2024 | Schimmel Paul53 | Director | Buy | 100,000 | $1.85 | $184,613.40 | +31.9% | +73.6% | +187.8% | |
| Jun 5, 2024 | Denyes Nancy | General Counsel | Buy | 5,000 | $1.86 | $9,276.00 | +29.0% | -2.2% | +194.0% |